Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes ...

Here are three important regulatory changes affecting parenteral packaging that pharmaceutical companies need to be aware of ...

Expanding Access to Lyophilized Therapies: Reunite removes reliance on vial kits and manual reconstitution, making ...

Ensuring fair drug pricing was a key promise of Sri Lanka’s government’s election manifesto, and that promise is finally ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...

AmacaThera has entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic.

Boehringer Ingelheim and CDR-Life have announced a worldwide licencing agreement for the development of CDR111, an antibody-based molecule targeting autoimmune conditions.

The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...

The resignation of the FDA's head drug regulator George Tidmarsh comes amid concerns about conduct related to lupus nephritis drug Lupkynis.

Their combined market capitalisation rose 4% from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025.

The ‘Risk to Reasons’ initiative aims to engage women and HCPs across the UK in non- judgemental conversations about HIV prevention.